Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991575 | 1.00 | MAPT (0.41) | MAPTADH1BADH1CADH1AADH4 | |
| SCHEMBL17027581 | 1.00 | MAPT (0.41) | MAPTADH1BADH1CADH1AADH4 | |
| SCHEMBL17027509 | 1.00 | MAPT (0.41) | MAPTADH1BADH1CADH1AADH4 | |
| SCHEMBL9356856 | 1.00 | MAPT (0.41) | MAPTADH1BADH1CADH1AADH4 | |
| SCHEMBL17027536 | 1.00 | MAPT (0.41) | MAPTADH1BADH1CADH1AADH4 | |
| SCHEMBL17027570 | 1.00 | MAPT (0.41) | MAPTADH1BADH1CADH1AADH4 | |
| SCHEMBL1987727 | 1.00 | MAPT (0.41) | MAPTADH1BADH1CADH1AADH4 | |
| SCHEMBL13750973 | 1.00 | MAPT (0.41) | MAPTADH1BADH1CADH1AADH4 | |
| SCHEMBL7990980 | 1.00 | MAPT (0.41) | MAPTADH1BADH1CADH1AADH4 | |
| SCHEMBL14861404 | 0.98 | OPRM1 (0.41) | MAPTADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-5319133-A | Isocyanates and their preparation using hypochlorous acid | OLIN CORPORATION (US) | 1994-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | MAPT 2535/4885ADH1B 2076/4885ADH1C 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.